• Appraise published research findings and current guideline recommendations on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer (PC), and counsel appropriate individuals regarding the potential benefits of systemic therapy.
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC, and apply this information in the discussion of nonresearch treatment options for patients.
• Explore available data with the use of treatment intensification with cytotoxic or secondary hormonal therapy for metastatic hormone-sensitive PC and effectively integrate these approaches into current clinical management algorithms.
• Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant PC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
• Assess the available and emerging research database supporting the use of PARP inhibitors for patients with mCRPC, and discern how to optimally incorporate these agents into current and future treatment plans for patients.
• Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the potential future clinical role of this strategy.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.
Topics to Be Discussed
MODULE 1: Management Approaches for Patients with Nonmetastatic Prostate Cancer
MODULE 2: Role of Treatment Intensification for Patients with Metastatic Hormone-Sensitive Prostate Cancer
MODULE 3: Selection and Sequencing of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer
MODULE 4: Current and Future Integration of PARP Inhibitors into the Management of Prostate Cancer
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.
CME credit form will be given to each participant at the conclusion of the activity.
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, and Pfizer Inc.